NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$125,279.00
Award Year:
2002
Program:
STTR
Phase:
Phase I
Contract:
1R41DA016033-01
Award Id:
60762
Agency Tracking Number:
DA016033
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ARGOLYN BIOSCIENCE, INC., 710 JOHNNIE DODDS BLVD, STE 202, MOUNT PLEASANT, SC, 29464
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
THOMASDIX
(843) 284-2202
TAD@ARGOLYN.COM
Business Contact:
GILBERTPEARSON
(843) 284-2202
MARSHDC@MUSC.EDU
Research Institute:
MEDICAL UNIVERSITY OF SOUTH CAROLINA

MEDICAL UNIVERSITY OF SOUTH CAROLINA
CHARLESTON, SC, 29208

Nonprofit college or university
Abstract
Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus far, application of the Argolyn technology to peptides of therapeutic interest has resulted in dramatic increases in receptor binding, induction of receptor selectivity, blood and plasma stabilization, and delivery through the blood brain barrier (BBB). A key question for our technology is its breadth: can any peptide of biological interest be improved? The Company currently has late-discovery-stage lead candidates in psychosis, pain, and thrombosis; the psychosis and thrombosis leads are being pursued through other STTRs (submitted) and currently active grants. In this proposal, we will use ABS17, our lead candidate in pain, as another vehicle with which to evaluate the robustness of the technology. We propose to evaluate the systemic pharmacokinetics, blood brain barrier access, oral bioavailability, microsomal stability, and preliminary toxicity of ABS17. Completion of the Specific Aims of this proposal, in combination with data already accumulated on this peptide, will "round out" the preclinical work and provide a third peptide candidate on which the Argolyn platform was successfully applied. It will also lead directly into the Phase 2 STTR that will address the technology more generically (immunogenicity, toxicity of the individual non-natural amino acid residues, and model peptides containing them, etc.).

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government